The first proof of concept studies have shown that a targeted delivery of a constitutively active DAPK2 to CD30-positive Hodgkin’s lymphoma cells selectively kills CD30-positive and DAPK2-negative but not CD30-positive and DAPK2-positive HL cells. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.